TY - JOUR T1 - The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. AU - Mbaeyi,Sarah, AU - Oliver,Sara E, AU - Collins,Jennifer P, AU - Godfrey,Monica, AU - Goswami,Neela D, AU - Hadler,Stephen C, AU - Jones,Jefferson, AU - Moline,Heidi, AU - Moulia,Danielle, AU - Reddy,Sujan, AU - Schmit,Kristine, AU - Wallace,Megan, AU - Chamberland,Mary, AU - Campos-Outcalt,Doug, AU - Morgan,Rebecca L, AU - Bell,Beth P, AU - Brooks,Oliver, AU - Kotton,Camille, AU - Talbot,H Keipp, AU - Lee,Grace, AU - Daley,Matthew F, AU - Dooling,Kathleen, Y1 - 2021/11/05/ PY - 2021/11/4/entrez PY - 2021/11/5/pubmed PY - 2021/11/6/medline SP - 1545 EP - 1552 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 70 IS - 44 N2 - Three COVID-19 vaccines are currently approved under a Biologics License Application (BLA) or authorized under an Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) and recommended for primary vaccination by the Advisory Committee on Immunization Practices (ACIP) in the United States: the 2-dose mRNA-based Pfizer-BioNTech/Comirnaty and Moderna COVID-19 vaccines and the single-dose adenovirus vector-based Janssen (Johnson & Johnson) COVID-19 vaccine (1,2) (Box 1). In August 2021, FDA amended the EUAs for the two mRNA COVID-19 vaccines to allow for an additional primary dose in certain immunocompromised recipients of an initial mRNA COVID-19 vaccination series (1). During September-October 2021, FDA amended the EUAs to allow for a COVID-19 vaccine booster dose following a primary mRNA COVID-19 vaccination series in certain recipients aged ≥18 years who are at increased risk for serious complications of COVID-19 or exposure to SARS-CoV-2 (the virus that causes COVID-19), as well as in recipients aged ≥18 years of Janssen COVID-19 vaccine (1) (Table). For the purposes of these recommendations, an additional primary (hereafter additional) dose refers to a dose of vaccine administered to persons who likely did not mount a protective immune response after initial vaccination. A booster dose refers to a dose of vaccine administered to enhance or restore protection by the primary vaccination, which might have waned over time. Health care professionals play a critical role in COVID-19 vaccination efforts, including for primary, additional, and booster vaccination, particularly to protect patients who are at increased risk for severe illness and death. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/34735422/The_Advisory_Committee_on_Immunization_Practices'_Interim_Recommendations_for_Additional_Primary_and_Booster_Doses_of_COVID_19_Vaccines___United_States_2021_ DB - PRIME DP - Unbound Medicine ER -